Anaplastic lymphoma kinase (ALK) is a potent oncogenic driver in lung cancer. ALK tyrosine kinase inhibitors yield significant benefit in patients with ALK fusion-positive (ALK+) lung cancers; yet the durability of response is limited by drug resistance. Elucidation of on-target resistance mechanisms...
Non-small cell lung cancer (NSCLC) is a heterogeneous disease, commonly defined by genetic alterations in oncogenic drivers. Targeted therapies have transformed the management of oncogene-driven lung cancers, with targeted agents now approved in the United States for 7 distinct molecular alteration...
ALK-positiveLungCancer KengoTakeuchi, 1 YoungLimChoi, 3 YukiTogashi, 1 ManabuSoda, 3 SatokoHatano, 1 KentaroInamura, 1 ShujiTakada, 3 ToshihideUeno, 3 YoshihiroYamashita, 3 YukitoshiSatoh, 2 SakaeOkumura, 2 KenNakagawa, 2 YuichiIshikawa, ...
Figure 1. Proposed therapeutic algorithm in ALK-positive NSCLC. ALK, anaplastic lymphoma kinase; cfDNA, cell-free DNA; NSCLC, non-small cell lung cancer; I.O. immunotherapy.References 1. P.L. Chia, T. John, A. Dobrovic, et al. Prevalence and natural history of ALK positive non-small-...
As a first-line treatment, crizotinib (Xalkori) improved progression-free survival (PFS) and objective response rate (ORR) compared with standard chemotherapy in patients with advanced ALK-positive non–small cell lung cancer (NSCLC).
Figure 1. Proposed therapeutic algorithm in ALK-positive NSCLC. ALK, anaplastic lymphoma kinase; cfDNA, cell-free DNA; NSCLC, non-small cell lung cancer; I.O. immunotherapy.References 1. P.L. Chia, T. John, A. Dobrovic, et al. Prevalence and natural history of ALK positive non-small-...
小细胞肺癌,non-small cell lung cancer(NSCLC)患者的肿 1.2.1实验方法525例肺癌组织标本经10%中性福尔马林瘤标本中首次发现。EML4-ALK融合基因是由ALK基因在2 固定后,常规石蜡包埋, 4 μm厚度切片。免疫组化采号染色体短臂内倒位inv(2) (p21p23)与其相邻的EML4基 用Envision法。兔单克隆抗体ALK(D5F3)抗体...
The study involved 347 patients with locally advanced or metastaticALK-positive lung cancer treated with 1 previous platinum-based regimen. Patients were randomized to oral crizotinib 250 mg twice daily, or to chemotherapy with intravenouspemetrexed(500 mg/m²) ordocetaxel(75 mg/m²) every 3 ...
Scientists from the University of Colorado Cancer Center have once again advanced the treatment of a specific kind of lung cancer. The team has documented how anaplastic lymphoma kinase (ALK) positive advanced non-small cell lung cancer (NSCLC) becomes r
A large team of medical researchers and doctors has found via phase III clinical trial that the ALK inhibitor lorlatinib is highly effective for treating non–small cell lung cancer (NSCLC).